Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial-Reference-Cited by-同舟云学术

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Published:2015-10 Issue:13 Volume:16 Page:1389-1398
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Grob Jean Jacques,Amonkar Mayur M,Karaszewska Boguslawa,Schachter Jacob,Dummer Reinhard,Mackiewicz Andrzej,Stroyakovskiy Daniil,Drucis Kamil,Grange Florent,Chiarion-Sileni Vanna,Rutkowski Piotr,Lichinitser Mikhail,Levchenko Evgeny,Wolter Pascal,Hauschild Axel,Long Georgina V,Nathan Paul,Ribas Antoni,Flaherty Keith,Sun Peng,Legos Jeffrey J,McDowell Diane Opatt,Mookerjee Bijoyesh,Schadendorf Dirk,Robert Caroline

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. NRAS mutation status is an independent prognostic factor in metastatic melanoma;Jakob;Cancer,2012

3. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

4. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

5. Targeted therapies: improved outcomes for patients with metastatic melanoma;Sondak;Nat Rev Clin Oncol,2011

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives;Cancer Management and Research;2024-07

2. Clinical Pharmacy Initiatives Contribute to the Excellent Efficacy of the Dabrafenib/Trametinib Combination for Iodine-Refractory Thyroid Carcinoma: A Case Report;Medicina;2024-06-25

3. Targeted therapies in ameloblastomas and amelobastic carcinoma—A systematic review;Oral Diseases;2024-05

4. Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma;2024-04-03

5. The treatment of advanced melanoma: Current approaches and new challenges;Critical Reviews in Oncology/Hematology;2024-04